266 related articles for article (PubMed ID: 34742178)
1. Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia.
Kim Y; Go TH; Jang J; Lee JB; Lim ST; Shim KY; Lee JI; Kong JH
Korean J Intern Med; 2021 Nov; 36(6):1450-1458. PubMed ID: 34742178
[TBL] [Abstract][Full Text] [Related]
2. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.
Hirji I; Gupta S; Goren A; Chirovsky DR; Moadel AB; Olavarria E; Victor TW; Davis CC
Health Qual Life Outcomes; 2013 Oct; 11():167. PubMed ID: 24099272
[TBL] [Abstract][Full Text] [Related]
4. Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO.
Haque R; Shi J; Chung J; Xu X; Avila C; Campbell C; Ahmed SA; Chen L; Schottinger JE
J Am Pharm Assoc (2003); 2017; 57(3):303-310.e2. PubMed ID: 28259737
[TBL] [Abstract][Full Text] [Related]
5. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
[TBL] [Abstract][Full Text] [Related]
6. Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort.
de Almeida MH; Pagnano KB; Vigorito AC; Lorand-Metze I; de Souza CA
Acta Haematol; 2013; 130(1):16-22. PubMed ID: 23363706
[TBL] [Abstract][Full Text] [Related]
7. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study.
Chen MT; Huang ST; Lin CW; Ko BS; Chen WJ; Huang HH; Hsiao FY
Oncologist; 2021 Nov; 26(11):974-982. PubMed ID: 34418220
[TBL] [Abstract][Full Text] [Related]
9. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Phuar HL; Begley CE; Chan W; Krause TM
Am J Clin Oncol; 2020 Jul; 43(7):517-525. PubMed ID: 32304434
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.
Wu EQ; Johnson S; Beaulieu N; Arana M; Bollu V; Guo A; Coombs J; Feng W; Cortes J
Curr Med Res Opin; 2010 Jan; 26(1):61-9. PubMed ID: 19905880
[TBL] [Abstract][Full Text] [Related]
12. Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary.
Batar P; Alizadeh H; Rokszin G; Abonyi-Toth Z; Demeter J
Pathol Oncol Res; 2024; 30():1611497. PubMed ID: 38444749
[No Abstract] [Full Text] [Related]
13. Tyrosine Kinase Inhibitor Dosing Patterns in Elderly Patients With Chronic Myeloid Leukemia.
Seo HY; Ko TH; Hyun SY; Song H; Lim ST; Shim KY; Lee JI; Kong JH
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):735-743.e2. PubMed ID: 31563565
[TBL] [Abstract][Full Text] [Related]
14. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
17. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
[TBL] [Abstract][Full Text] [Related]
18. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
20. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto KJ; Fujita H; Fujioka I; Kimura Y; Aisa Y; Iwanaga E; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
Med Oncol; 2018 May; 35(7):99. PubMed ID: 29846829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]